Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Manipal Health Enterprises / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/manipal-health-enterprises-limited" target="_blank" data-smartkarma-citation="entities:57525:1" rel="noopener">Manipal Health Enterprises (MANIPALH IN)</a> has redeemed the outstanding NCDs worth of INR53B, using the IPO proceeds. The debt reduction is expected to support the company's focus on profitable growth.</li>
<li>Manipal Health has other strong margin drivers. The integration of Sahyadri Hospitals, increasing contribution of high-acuity specialties, and ramping-up of greenfield expansions are key margin drivers.</li>
<li>With long-term structural factors supporting growth of the Indian healthcare delivery market, as a large player with Pan-India presence, Manipal Health is well-positioned to leverage on the growth opportunity.  </li>
</ul>



Manipal Health Enterprises (MANIPALH IN) has redeemed the outstanding NCDs worth of INR53B, using the IPO proceeds. The debt reduction is expected to support the company's focus on profitable growth.
Manipal Health has other strong margin drivers. The integration of Sahyadri Hospitals, increasing contribution of high-acuity specialties, and ramping-up of greenfield expansions are key margin drivers.
With long-term structural factors supporting growth of the Indian healthcare delivery market, as a large player with Pan-India presence, Manipal Health is well-positioned to leverage on the growth opportunity.  


Manipal Health Enterprises (MANIPALH IN): Debt Repayment Done; What Are Next Margin Levers

Thematic (Sector/Industry)

<ul>
<li>CStone Pharmaceuticals got additional indication approval for sugemalimab from UK MHRA in NSCLC. HBM Holdings entered into an exclusive license agreement and equity partnership agreement with Solstice Oncology.</li>
<li>Astellas Pharma and Vir Biotechnology entered a global strategic collaboration to advance VIR-5500 for prostate cancer. Bora Pharmaceuticals has renewed a five-year manufacturing partnership with GSK.</li>
<li>Lupin received EC approval for ranibizumab biosimilar. Zydus Lifesciences announces successful clinical development of pembrolizumab biosimilar candidate FYB206. FDA has accepted for review Dr. Reddy’s Laboratories’ BLA for Orencia biosimilar.</li>
</ul>


CStone Pharmaceuticals got additional indication approval for sugemalimab from UK MHRA in NSCLC. HBM Holdings entered into an exclusive license agreement and equity partnership agreement with Solstice Oncology.
Astellas Pharma and Vir Biotechnology entered a global strategic collaboration to advance VIR-5500 for prostate cancer. Bora Pharmaceuticals has renewed a five-year manufacturing partnership with GSK.
Lupin received EC approval for ranibizumab biosimilar. Zydus Lifesciences announces successful clinical development of pembrolizumab biosimilar candidate FYB206. FDA has accepted for review Dr. Reddy’s Laboratories’ BLA for Orencia biosimilar.


APAC Healthcare Weekly (March 1) – CStone, HBM, Astellas, Bora Pharma, Lupin, Zydus Lifesciences

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Event-Driven

HealthCare Global Enterprises / Event-Driven

<ul>
<li>The Supreme Court has questioned medicine markups and sought government consideration of wider margin restrictions; a universal 16% cap is not yet established.</li>
<li>Earnings exposure depends on drug billing, procurement economics, and contract terms, while restrictions on captive pharmacy purchases could create a separate volume risk.</li>
<li>Investors should distinguish recoverable earnings pressure from weaker pricing power, then assess whether expansion returns justify existing valuation assumptions.</li>
</ul>


The Supreme Court has questioned medicine markups and sought government consideration of wider margin restrictions; a universal 16% cap is not yet established.
Earnings exposure depends on drug billing, procurement economics, and contract terms, while restrictions on captive pharmacy purchases could create a separate volume risk.
Investors should distinguish recoverable earnings pressure from weaker pricing power, then assess whether expansion returns justify existing valuation assumptions.


Supreme Court Drug-Pricing Scrutiny in India: Which Hospital Earnings Are Actually Exposed?

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ihh-healthcare-bhd" target="_blank" data-smartkarma-citation="entities:876:1" rel="noopener">IHH Healthcare (IHH MK)</a> is facing a legal headwind after a Tokyo District Court dismissed its damage claims against Daiichi Sankyo related to the acquisition of Fortis Healthcare.</li>
<li>However, accelerated growth momentum reported in 2Q26 financial result, in particular recovery in Singapore operation, raises conviction on the strength of the core operation of IHH.</li>
<li>Amid rising demand, IHH remains confident in its growth path. The company has reaffirmed 2026 EBITDA and PATMI margins guidance at 22–24% and 8–10%, respectively.</li>
</ul>



IHH Healthcare (IHH MK) is facing a legal headwind after a Tokyo District Court dismissed its damage claims against Daiichi Sankyo related to the acquisition of Fortis Healthcare.
However, accelerated growth momentum reported in 2Q26 financial result, in particular recovery in Singapore operation, raises conviction on the strength of the core operation of IHH.
Amid rising demand, IHH remains confident in its growth path. The company has reaffirmed 2026 EBITDA and PATMI margins guidance at 22–24% and 8–10%, respectively.


IHH Healthcare (IHH MK): Faster Growth Momentum in 2Q Raises Hope Amid Persisting Legal Headwinds

<ul>
<li>Takeda has dropped AstraZeneca-partnered antibody drug candidate from its pipeline. Eisai and Merck are closing late-stage trial of Lenvima plus Keytruda in hepatocellular carcinoma on disappointing result.</li>
<li>Wuxi AppTec sharpens CRDMO business by selling its China-based clinical research subsidiaries. FDA has designated Celltrion’s Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.</li>
<li>CSL is delaying demerger of CSL Seqirus ‘to maximise shareholder value.’ PharmaEssentia has filed for the additional indication of Besremi for Essential Thrombocythemia (ET) with the FDA.</li>
</ul>


Takeda has dropped AstraZeneca-partnered antibody drug candidate from its pipeline. Eisai and Merck are closing late-stage trial of Lenvima plus Keytruda in hepatocellular carcinoma on disappointing result.
Wuxi AppTec sharpens CRDMO business by selling its China-based clinical research subsidiaries. FDA has designated Celltrion’s Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.
CSL is delaying demerger of CSL Seqirus ‘to maximise shareholder value.’ PharmaEssentia has filed for the additional indication of Besremi for Essential Thrombocythemia (ET) with the FDA.


APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia

India

Apollo Hospitals Enterprise Limited owns and operates hospitals in India.  The Company also runs a 24-hour pharmacy network via over 120 outlets across India. Apollo Hospitals also runs clinics and offer managed care and family health plans. The Company has a variety of locations in Chennai, Hyderabad, Delhi, Dubai, Vizag, Bilaspur and Chengannur.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Apollo Hospitals Enterprise (APHS IN)

Manipal Health Enterprises (MANIPALH IN): Debt Repayment Done; What Are Next Margin Levers

Manipal redeemed outstanding NCDs worth of INR53B, using IPO proceeds. Debt reduction should support profitable growth. Integration of Sahyadri...

Tina Banerjee

APAC Healthcare Weekly (March 1) – CStone, HBM, Astellas, Bora Pharma, Lupin, Zydus Lifesciences

CStone’s sugemalimab got label expansion in UK. HBM Holdings entered exclusive license agreement with Solstice Oncology. Astellas Pharma and Vir...

Tina Banerjee

Supreme Court Drug-Pricing Scrutiny in India: Which Hospital Earnings Are Actually Exposed?

As the Supreme Court targets hospital drug markups, which earnings are actually exposed? Read our breakdown of true margin risks beyond headline...

Nimish Maheshwari

IHH Healthcare (IHH MK): Faster Growth Momentum in 2Q Raises Hope Amid Persisting Legal Headwinds

IHH is facing a legal headwind after a Tokyo Court dismissed its damage claims against Daiichi Sankyo. However, accelerated momentum reported in...

Tina Banerjee

APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia

Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus....

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)